Here, we demonstrated that VDAC1 silencing highly reduced the expression of CSC markers in GBM and lung and breast cancer, as revealed using IHC, immunoblotting or q-RT-PCR (Figure 4, Figure S1B). This evidence concerns the gene VDAC1 and glioblastoma.